In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Immatics raises €53.8mm through Series C round

Executive Summary

Immatics biotechnologies GMBH (therapeutic cancer vaccines) raised €53.8mm ($70.4mm) through its Series C round. Over half of the money came from returning investors including dievini Hopp Biotech Holding (now immatics' largest shareholder), Wellington Partners, and others, with additional participation from new buyers AT Impf GMBH and funds advised by MIG. Proceeds will be used to initiate Phase III renal cell carcinoma trials with immatics' lead cancer vaccine IMA901. Including the Series C round, the ten-year-old company has now raised over €100mm.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies